biotech · Bile acid diarrhoea · Transthyretin cardiac amyloidosis · GLUE
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker GLUE. Primary therapeutic focus areas include Bile acid diarrhoea, Transthyretin cardiac amyloidosis, Lactati
Boston, USA HQ
213 Employees
Public company Type
GLUE · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 213
- Programs
- 7
- Drugs
- 14
- Patents
- 72
Vyndaqel 61 mg soft capsules
Approved · small molecule · Transthyretin cardiac amyloidosis
Vyndaqel 61 mg soft capsules for Transthyretin cardiac amyloidosis is a Approved program (small_molecule) at Monte Rosa Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MGNT2022
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Monte Rosa Therapeutics
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Transthyretin cardiac amyloidosis
- Status
- active
- Trials
- 1